Cobra provides GMP manufacture of mammalian derived therapeutics proteins (monoclonal antibodies) and biosimilars, following Good Manufacturing Practices
of production and testing to ensure quality products for customers’ preclinical and clinical trials through to commercial supply.
Processes are clearly defined, controlled and validated to ensure compliance, clear records are made, and any deviations are investigated and documented. We are able to provide a certificate of
cGMP compliance and GMP campaign summary report with QA review of completed documentation.
In 1995 we manufactured our first protein, a monoclonal antibody (mAb) to target stem cells, and since then we have manufactured a diverse range of proteins and biosimilars, including vaccines for malaria and meningitis, and disease-modifying protein therapies for arthritis, conjunctivitis and hepatitis B and C.